SCHEMBL16248331

SCHEMBL16248331

Cc1nc2cc(NC(=O)C3CC3)ccc2s1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
RAB9A P51151 8/20 0.60
MAPT P10636 3/20 0.60
KDM4E B2RXH2 1/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
TRPV1 Q8NER1 2/20 0.57
CASP3 P42574 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
CHRM5 P08912 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
LMNA P02545 2/20 0.54
ALDH1A1 P00352 1/20 0.53
ALOX15 P16050 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
LDHA P00338 1/20 0.53
ABCB1 P08183 1/20 0.53
ABCC1 P33527 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2073200 0.88 MCHR1 (0.56) NPC1RAB9AMAPTKDM4ESMN1; SMN2
SCHEMBL5798843 0.83 RAB9A (0.65) NPC1RAB9AMAPTKDM4ESMN1; SMN2
SCHEMBL28983104 0.82 CHRM5 (0.73) MAPTSMN1; SMN2CHRM5LMNAALDH1A1
SCHEMBL28983145 0.82 CHRM5 (0.73) MAPTSMN1; SMN2CHRM5LMNAALDH1A1
SCHEMBL4011536 0.81 LDHA (0.78) NPC1RAB9AMAPTKDM4ESMN1; SMN2
SCHEMBL28983152 0.81 CHRM5 (0.72) MAPTKDM4ESMN1; SMN2CHRM5LMNA
SCHEMBL28983186 0.81 CHRM5 (0.71) MAPTSMN1; SMN2CHRM5LMNAALDH1A1
SCHEMBL28983188 0.81 CHRM5 (0.71) MAPTSMN1; SMN2CHRM5L3MBTL1LMNA
SCHEMBL28983123 0.80 ALDH1A1 (0.86) NPC1RAB9AMAPTSMN1; SMN2CHRM5
SCHEMBL28983167 0.80 CHRM5 (0.62) MAPTSMN1; SMN2CHRM5LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981086-B2 Phosphine-ligated palladium sulfonate palladacycles MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2015-03-17 US disclosed
US-20150045570-A1 PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-12 US disclosed
US-8889857-B2 Phosphine-ligated palladium sulfonate palladacycles MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2014-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045570-A1 PHOSPHINE-LIGATED PALLADIUM SULFONATE PALLADACYCLES PHOSPHO1, PDCD1, PDCD1LG2 NPC1 4689/4885RAB9A 474/4885MAPT 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.